Open AccessRTKN2 is Associated with Unfavorable Prognosis and Promotes Progression in Non-Small-Cell Lung Cancer
Author(s) -
Lupeng Ji,
Yujuan Huang,
Yi Zhang,
Anping Peng,
Jilong Qin,
Shaofan Lu,
Yu-Shan Huang
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s260436
Subject(s) - mmp2 , gene silencing , lung cancer , apoptosis , cancer research , a549 cell , cell growth , biomarker , mmp9 , cancer , medicine , biology , metastasis , oncology , downregulation and upregulation , gene , genetics
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. However, the molecular mechanism of NSCLC remains unknown. Accumulating data show that Rhotekin 2 (RTKN2) functions as a novel crucial regulator of diverse biological processes; however, its pathological role in NSCLC remains unclear.